Home  »  Business   »  BIOLASE Inc. (BIOL): Skating on Thin Ice? We Know ...

BIOLASE Inc. (BIOL): Skating on Thin Ice? We Know the Answer

BIOLASE Inc. (NASDAQ:BIOL) went down by -39.75% from its latest closing price compared to the recent 1-year high of $13.83. The company’s stock price has collected -42.60% of loss in the last five trading sessions.

Is It Worth Investing in BIOLASE Inc. (NASDAQ :BIOL) Right Now?

Plus, the 36-month beta value for BIOL is at 1.48. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for BIOLASE Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


The average price from analysts is $9.50, which is $8.53 above the current price. BIOL currently public float of 7.01M and currently shorts hold a 1.81% ratio of that float. Today, the average trading volume of BIOL was 33.89K shares.

BIOL’s Market Performance

BIOL stocks went down by -42.60% for the week, with a monthly drop of -50.51% and a quarterly performance of -74.81%, while its annual performance rate touched -90.76%. The volatility ratio for the week stands at 20.35% while the volatility levels for the past 30 days are set at 11.53% for BIOLASE Inc. The simple moving average for the period of the last 20 days is -43.78% for BIOL stocks with a simple moving average of -80.58% for the last 200 days.

Analysts’ Opinion of BIOL

Many brokerage firms have already submitted their reports for BIOL stocks, with The Benchmark Company repeating the rating for BIOL by listing it as a “Speculative Buy.” The predicted price for BIOL in the upcoming period, according to The Benchmark Company is $2 based on the research report published on June 19th of the previous year 2019.

Singular Research, on the other hand, stated in their research note that they expect to see BIOL reach a price target of $2.50. The rating they have provided for BIOL stocks is “Buy” according to the report published on April 25th, 2017.

WallachBeth gave a rating of “Hold” to BIOL, setting the target price at $2.50 in the report published on May 13th of the previous year.

BIOL Trading at -54.71% from the 50-Day Moving Average

After a stumble in the market that brought BIOL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.99% of loss for the given period.

Volatility was left at 11.53%, however, over the last 30 days, the volatility rate increased by 20.35%, as shares sank -52.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -70.34% lower at present.

During the last 5 trading sessions, BIOL fell by -42.60%, which changed the moving average for the period of 200-days by -90.53% in comparison to the 20-day moving average, which settled at $1.6715. In addition, BIOLASE Inc. saw -90.05% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BIOL starting from LORD JONATHAN T MD, who sale 11,038 shares at the price of $0.38 back on Dec 15. After this action, LORD JONATHAN T MD now owns 633,096 shares of BIOLASE Inc., valued at $4,194 using the latest closing price.

BEAVER JOHN R, the President & CEO of BIOLASE Inc., purchase 70,000 shares at $0.45 during a trade that took place back on Nov 30, which means that BEAVER JOHN R is holding 621,530 shares at $31,500 based on the most recent closing price.

Stock Fundamentals for BIOL

Current profitability levels for the company are sitting at:

  • -41.12 for the present operating margin
  • +42.18 for the gross margin

The net margin for BIOLASE Inc. stands at -41.23.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.57.

Is CVS Health Corporation (CVS) a Keeper?

CVS Health Corporation (NYSE:CVS) went up by 0.55% from its latest closing price compared to the recent 1-year high of $111.25. The company’s stock price